Alison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.
Alison J. Moskowitz, MD
Advertisement
Articles by Alison J. Moskowitz, MD
Alison J. Moskowitz, MD, discusses important updates in Hodgkin lymphoma.
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
Advertisement
Latest Updated Articles
Dr. Moskowitz on the ALCANZA Trial in CTCLPublished: March 30th 2018 | Updated:
Dr. Moskowitz on Important Updates in Hodgkin LymphomaPublished: January 21st 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
5